Marco Di Battista

Sep 1, 2024 | jrheum.org | Marco Di Battista |Alessandra Della Rossa |Marta Mosca |M. Di Battista

Long-Term Data on Efficacy and Safety of Selexipag for Digital Systemic Sclerosis Vasculopathy Marco Di Battista, Alessandra Della Rossa, Marta Mosca The Journal of Rheumatology Sep 2024, 51 (9) 899-903; DOI: 10.3899/jrheum.2024-0103

Jun 24, 2024 | jrheum.org | Marco Di Battista |Marta Mosca |M. Di Battista |Rheumatology Unit

AbstractObjective Raynaud phenomenon (RP) and digital ulcers (DUs) are the main signs of digital vasculopathy in systemic sclerosis (SSc). Selexipag is an oral prostacyclin agonist approved for SSc-related pulmonary arterial hypertension. Following our previous preliminary short-course report, we herein present long-term data on selexipag safety and efficacy in the treatment of SSc digital vasculopathy.

Jun 7, 2024 | jrheum.org | Marco Di Battista |Alessandra Della Rossa |Marta Mosca |M. Di Battista

Long-term data on efficacy and safety of selexipag for scleroderma digital vasculopathy Marco Di Battista, Alessandra Della Rossa, Marta Mosca The Journal of Rheumatology Jun 2024, jrheum.2024-0103; DOI: 10.3899/jrheum.2024-0103